Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -192.68% | 58.96% | 80.72% | 71.99% | 77.10% |
| Total Depreciation and Amortization | -8.15% | -11.48% | -12.27% | -13.03% | -11.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 167.06% | -28.49% | -60.84% | -34.17% | -38.31% |
| Change in Net Operating Assets | -504.17% | 737.50% | -245.39% | -149.33% | -105.32% |
| Cash from Operations | -8.85% | 60.41% | -31.09% | -7.03% | -13.96% |
| Capital Expenditure | 5.32% | 11.11% | 6.32% | 3.58% | 4.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -36.76% | -57.14% | -86.75% | 46.67% | 0.00% |
| Other Investing Activities | -11.50% | 4.80% | 5.09% | 19.91% | 24.87% |
| Cash from Investing | -18.18% | 6.71% | 1.13% | 37.93% | 47.79% |
| Total Debt Issued | -- | -100.00% | -71.44% | -71.44% | -- |
| Total Debt Repaid | 66.18% | 71.23% | 37.14% | 62.40% | -254.42% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 29.25% | -70.50% | -128.47% | -188.71% | -81.20% |
| Cash from Financing | 6.38% | 17.33% | -18.73% | 38.10% | -28.73% |
| Foreign Exchange rate Adjustments | -480.00% | -68.75% | -3,833.33% | -197.96% | 75.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.42% | 13,462.50% | -171.16% | 1,201.35% | -38.21% |
